SCHEMBL934740

SCHEMBL934740

Nc1ncc(Br)nc1Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 2/20 0.46
AOC3 Q16853 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ATR Q13535 1/20 0.42
MAPKAPK2 P49137 1/20 0.40
MPO P05164 1/20 0.40
CALM1 P0DP23 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23440398 0.92 LTB4R (0.41) LTB4RAOC3CYP1A2CYP3A4CYP2D6
SCHEMBL29769271 0.83 ATR (0.40) LTB4RAOC3CYP1A2CYP3A4CYP2D6
Ammonia Solution, Strong SCHEMBL557826 0.83 MAOA (0.41) AOC3CYP2D6ATRMAPKAPK2MPO
SCHEMBL14898963 0.82 LTB4R (0.46) LTB4RAOC3CYP1A2CYP3A4CYP2D6
Ammonia Solution, Strong SCHEMBL5381714 0.81 MPO (0.35) MPO
SCHEMBL21751424 0.81 LTA4H (0.43) MAPKAPK2MPO
SCHEMBL30800174 0.81 LTA4H (0.43) MAPKAPK2MPO
SCHEMBL13247444 0.81 MAPKAPK2 (0.51) LTB4RAOC3CYP1A2CYP3A4CYP2D6
SCHEMBL22651726 0.81 LTB4R (0.45) LTB4RAOC3CYP1A2CYP3A4CYP2D6
SCHEMBL23440396 0.81 PRKDC (0.48) CYP2D6ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239803-A1 SYNTHESIS OF COELENTERAZINE INTERNATIONAL PAPER COMPANY 2024-07-18 US claimed
US-11939332-B2 Synthesis of coelenterazine INTERNATIONAL PAPER COMPANY (US) 2024-03-26 US claimed
EP-3830088-A1 SYNTHESIS OF COELENTERAZINE International Paper Company (US) 2021-06-09 EP claimed
US-11008326-B2 Synthesis of coelenterazine INTERNATIONAL PAPER COMPANY (US) 2021-05-18 US claimed
US-20210070762-A1 SYNTHESIS OF COELENTERAZINE INTERNATIONAL PAPER COMPANY (US) 2021-03-11 US claimed
CN-112368286-A Synthesis of coelenterazine 国际纸业公司 2021-02-12 CN claimed
US-10906911-B2 2021-02-02 US claimed
EP-3981839-B1 COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS PROMEGA CORP (US) 2025-08-20 EP disclosed
JP-2024153780-A Synthesis of coelenterazine インターナショナル・ペーパー・カンパニー 2024-10-29 JP disclosed
US-20240239803-A1 SYNTHESIS OF COELENTERAZINE INTERNATIONAL PAPER COMPANY 2024-07-18 US disclosed
US-20240239803-A1 SYNTHESIS OF COELENTERAZINE INTERNATIONAL PAPER COMPANY 2024-07-18 US disclosed
US-20240239803-A1 SYNTHESIS OF COELENTERAZINE INTERNATIONAL PAPER COMPANY 2024-07-18 US disclosed
CN-117924295-A Furimazine derivative and preparation method and application thereof 广州博鹭腾生物科技有限公司 2024-04-26 CN disclosed
EP-2454261-A1 IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE Universita Degli Studi di Siena (IT) 2012-05-23 EP disclosed
WO-2012040105-A2 RENILLA/GAUSSIA TRANSFECTED CELLS AS A LIGHT SOURCE FOR IN-SITU PHOTODYNAMIC THERAPY OF CANCER KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-03-29 WO disclosed
US-20110288280-A1 COELENTERAMIDE ANALOGS TOKYO INSTITUTE OF TECHNOLOGY (JP) 2011-11-24 US disclosed
US-20110288280-A1 COELENTERAMIDE ANALOGS TOKYO INSTITUTE OF TECHNOLOGY (JP) 2011-11-24 US disclosed
US-20110288280-A1 COELENTERAMIDE ANALOGS TOKYO INSTITUTE OF TECHNOLOGY (JP) 2011-11-24 US disclosed
WO-2011007314-A1 IMIDAZO[1,2-α]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE UNIVERSITÀ DEGLI STUDI DI SIENA (IT) 2011-01-20 WO disclosed
WO-2011007314-A1 IMIDAZO[1,2-α]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE UNIVERSITÀ DEGLI STUDI DI SIENA (IT) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288280-A1 COELENTERAMIDE ANALOGS CCKAR, ARSA, SI LTB4R 1309/4885AOC3 1594/4885CYP1A2 2681/4885
US-11939332-B2 Synthesis of coelenterazine ACHE, UROD, DDT LTB4R 2170/4885AOC3 223/4885CYP1A2 144/4885
US-11008326-B2 Synthesis of coelenterazine ACHE, UROD, DDT LTB4R 2170/4885AOC3 223/4885CYP1A2 144/4885
US-20240239803-A1 SYNTHESIS OF COELENTERAZINE ACHE, UROD, DDT LTB4R 2170/4885AOC3 223/4885CYP1A2 144/4885
US-20210070762-A1 SYNTHESIS OF COELENTERAZINE ACHE, UROD, DDT LTB4R 2170/4885AOC3 223/4885CYP1A2 144/4885
US-10906911-B2 ACHE, UROD, SI LTB4R 1847/4885AOC3 222/4885CYP1A2 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.